clinical trial · NCT05170126
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Bristol-Myers Squibb·—·recruiting·n = 1,182
Multiple Sclerosis
brief summary
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
started
Jul 15, 2022
primary completion
Jun 30, 2032
completion
Jun 30, 2032
last updated
Nov 20, 2025
official title
ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol